Home » Newsletters » BioWorld Science

BioWorld Science

May 17, 2001

View Archived Issues

NIH licensing opportunity: HIV fusion proteins with increased immunogenicity

Licensing opportunity from NIH: E-selectin as treatment/prevention for brain injury

Tissue distribution and toxicity of EpiGenesis's RASON assessed

phVEGF-2 therapy shows promising results in human pilot study

New selective inhibitor of T-cell IL-5 synthesis promising for eosinophilic inflammation

Cytokine delivery using a biodegradable polymer system promotes bone formation and repair

Clinical trial results with Thalomid in early-stage and refractory multiple myeloma reported

Carafiban maleate, an orally active fibrinogen antagonist with clinical potential

Preclinical data support IL-13 receptor as a target for the therapy of glioblastoma

Eligix to begin phase III evaluation of BCell-HDM system

Murine and monkey studies demonstrate effective stem cell mobilization with SB-251353

XTL-001 enters phase II trial for chronic hepatitis B

BioSante begins phase II trial of testosterone gel for treatment of FSD

Phytera and Gemin X establish alliance for discovery of novel anticancer agents

Intellivax now part of ID Biomedical

ConjuChem completes phase I trial of anticlotting compound

Antitumor efficacy of SarCNU correlated with EMT and MGMT expression

Biomed-101 increases drug tolerance in phase I renal cancer trial

BioMedicines completes phase II enrollment of U.S. interferon omega trial

Serono and Alkermes to develop sustained-release formulation of rhFSH

EMD-221963, a representative NHE-3 inhibitor from Merck KGaA

New antiarrhythmic agents designed by Nissan to have fewer side effects

Highly effective HIV protease inhibitors designed by Tibotec and NIH

Novo Nordisk presents new compounds for diabetes and related disorders

Substituted biphenyls act as glucagon receptor antagonists, as reported by Bayer

Neurogen and Pfizer codevelop new NPY Y1 antagonists, describe potential uses

Company Profile: Lapid Pharmaceuticals

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Cosmo data positive for first new hair-loss approach in decades
BioWorld
Shares of Cosmo Pharmaceuticals NV rose sharply on Dec. 3 following top-line pivotal phase III data showing a statistically significant and clinically meaningful...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...